IP Library › Granted Patent US 10,881,638
Granted Patent B2
US 10,881,638 · App. 15/557,103 · Granted Jan 5, 2021

Eye health composition

Inventors: Céline Olmiere (Vertaizon, FR); Fabrice Mercier (Clermont-Ferrand, FR)
Assignee: LABORATOIRES THEA
A61K31/375A61K9/0053A61K9/4858A61K31/047A61K31/05A61K31/07A61K31/202A61K31/355A61K33/30A61K33/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,881,638
App. No.
15/557,103
Granted
Jan 5, 2021
Kind
B2
Abstract

Ophthalmic nutraceutical composition comprising: vitamins; trace elements; carotenoids; omega-3 fatty acids; and resveratrol.

Claims (27)

1. A method of treating an eye pathology caused by an overexpression of a vascular endothelial growth factor (VEGF) pathway in a subject in need thereof, the method comprising:

administering to the subject a daily dose composition consisting of:

120 mg to 240 mg of vitamin C;

10 mg to 500 mg of vitamin E;

5 mg to 100 mg of zinc;

0.2 mg to 10 mg of copper;

2 mg to 50 mg of the lutein;

0.5 mg to 10 mg of zeaxanthin;

fish oil comprising:

172 mg to 380 mg of EPA; and

190 to 366 mg of DHA; and

30 to 200 mg of resveratrol,

wherein said eye pathology is selected from the group consisting of exudative age-related macular degeneration (AMD), retinal venous occlusion, macular edema, diabetic macular edema, myopia, diabetic retinopathy, neovascular glaucoma, and corneal neovascularization.

2. The method according to claim 1 , wherein the composition consists of:

120 mg to 240 mg of vitamin C;

30 mg of vitamin E;

12.5 mg of zinc;

1 mg of copper;

10 mg of the lutein;

2 mg of zeaxanthin;

fish oil comprising:

172 mg to 380 mg of EPA; and

190 to 366 mg of DHA; and

30 mg of resveratrol.

3. The method according to claim 1 , wherein said subject is suffering from symptoms of said pathology only in one eye.

4. The method according to claim 1 , wherein the composition is administered orally.

5. The method according to claim 1 , wherein the composition is formulated as a capsule, a tablet, or a pill.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2017
From: OLMIERE, CÉLINE; MERCIER, FABRICE
To: LABORATOIRES THEA
Reel/Frame 043818/0088 →
Priority Claims (1)
FR 1552483 · Mar 25, 2015 · national
Continuity (1)
Related Publication 20180042894A1 · Feb 15, 2018